There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied Therapeutics (APLT – Research Report), Vor Biopharma (VOR – Research Report) and Eliem Therapeutics (ELYM – Research Report) with bullish sentiments.
Applied Therapeutics (APLT)
In a report released yesterday, Brian Skorney from Robert W. Baird maintained a Buy rating on Applied Therapeutics, with a price target of $18.00. The company’s shares closed last Thursday at $2.42, close to its 52-week low of $1.45.
According to TipRanks.com, Skorney has 0 stars on 0-5 stars ranking scale with an average return of
Applied Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.25.
Vor Biopharma (VOR)
In a report issued on April 6, Jack Allen from Robert W. Baird maintained a Buy rating on Vor Biopharma, with a price target of $38.00. The company’s shares closed last Thursday at $6.28, close to its 52-week low of $5.65.
According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $33.20.
Eliem Therapeutics (ELYM)
Leerink Partners analyst Marc Goodman initiated coverage with a Buy rating on Eliem Therapeutics on April 6 and set a price target of $33.00. The company’s shares closed last Thursday at $8.40, close to its 52-week low of $7.97.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eliem Therapeutics with a $33.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLT:
- Evercore ISI Sticks to Their Hold Rating for Ocado Group (OCDGF)
- Evercore ISI Keeps Their Buy Rating on RPM International (RPM)
- Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Evercore ISI
- Evercore ISI Maintains Their Buy Rating on Valaris (VAL)
- Evercore ISI Sticks to Its Buy Rating for Apollo Global Management (APO)